|
Vol. 12.08 – 1 March, 2023
|
|
|
|
|
|
Investigators observed that polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) were remarkably enriched in the tumor microenvironment of CCL20-overexpressing cancer cell orthotopic allograft tumors. [Signal Transduction and Targeted Therapy]
|
|
|
|
|
PUBLICATIONSRanked by the impact factor of the journal
|
|
|
|
|
Researchers identified a mitochondria-encoded circular RNA termed mcPGK1, mitochondrial circRNA for translocating phosphoglycerate kinase 1, which was highly expressed in liver tumor-initiating cells.
[Nature Communications]
|
|
|
|
|
Investigators introduced a nanomaterial-based approach to photothermally induce the differentiation of CSCs, termed “photothermal differentiation”, leading to the attenuation of cancer cell stemness, chemoresistance, and metastasis. [Nano Letters]
|
|
|
|
|
Scientists designed a hyaluronic acid-coated siProminin2-loaded FeOOH nano-drug to accelerate ferroptosis of breast CSCs by simultaneously increasing iron ion content, inhibiting iron efflux, and scavenging glutathione.
[Acta Biomaterialia]
|
|
|
|
|
Researchers reported that Plexin B3 (PLXNB3) expression was increased in response to hypoxia and that PLXNB3 was a direct target gene of hypoxia-inducible factor 1 in human breast cancer cells.
[Cell Reports]
|
|
|
|
|
The authors pinpointed OPA1high with mitochondrial fusion as a metabolic feature of human lung CSCs, licensing their stem-like properties.
[JCI Insight]
|
|
|
|
|
The up-regulation of FBXL8 promoted the proliferation, invasion, and migration of colorectal cancer tumor cells and maintained the stem-cell characteristics of colorectal tumor cells.
[Clinical and Translational Medicine]
|
|
|
|
|
In order to target stem cells in ovarian cancer, scientists used the sortase reaction to site-specifically conjugate the potent cytotoxin monomethyl auristatin E and their co-receptors ZNRF3 and RNF43 via a protease-cleavable linker.
[Journal of Pharmacology and Experimental Therapeutics]
|
|
|
|
|
Investigators evaluated the effect of the tetrose saccharide, erythrose, a neuroleukin inhibitor of invasiveness and drug sensitization in glioblastoma stem cells. [Medical Oncology]
|
|
|
|
|
|
The authors review up-to-date knowledge of the relationship between m6A modulation and drug resistance and discuss the regulation of m6A modulation in epithelial-mesenchymal transition and CSCs. [Heliyon]
|
|
|
|
|
|
Tachyon Therapeutics, Inc. announced that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $7.1 million grant to support a Phase I clinical study of TACH101 in patients with advanced solid tumors. [Tachyon Therapeutics, Inc.]
|
|
|
|
|
|
April 23 – 28, 2023 Cancun, Mexico
|
|
|
|
|
|
|
Albert Einstein College of Medicine – New York, New York, United States
|
|
|
|
|
Weill Cornell College of Medicine – New York, New York, United States
|
|
|
|
|
Penn Medicine – Philadelphia, Pennsylvania, United States
|
|
|
|
|
The Henry Ford Health System – Detroit, Michigan, United States
|
|
|
|
|
The University of Melbourne – Melbourne, Australia
|
|
|
|
|